Braftovi/Mektovi (encorfenib/binimetinib)

pCPA File Number: 21544
Negotiation Status:
Under consideration for negotiation
Indication(s):
Braftovi (encorafenib) and Mektovi (binimetinib), in combination, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600 mutation, as detected by a validated test
Sponsor/Manufacturer:
PFIZER CANADA ULC
CADTH Project Number:
PC0232-000
pCPA Engagement Letter Issued:
Not Applicable
Negotiation Process Concluded:
Not Applicable